Ongoing assessment for toxicities/late effects
In patients with breast cancer ensure that follow-up care includes ongoing assessment and supportive care for possible long-term toxicities and late effects of adjuvant treatments (including secondary cancers, cardiovascular toxicity, lymphoedema, mental health (including distress, depression, anxiety, body image), sexual health, premature menopause, infertility, fatigue, weight gain, impaired cognitive function, musculoskeletal health, pain and neuropathy, and bone health).
In view of the long potential life expectancy, particular attention should be paid to possible long-term toxicities of adjuvant treatments (e.g. secondary cancers, cardiovascular toxicity, irreversible ovarian failure, weight gain, cognitive function, bone health). Clinics dedicated to the assessment and management of early and late treatment side effects and adherence to treatment and follow-up guidelines should be developed
How this guidance was developed
No evidence-based source recommendation was identified for this topic, which was considered an important aspect of care. This practice point was developed using an expert consensus process. The practice point was informed by a source recommendation in the ESO-ESMO 2017 consensus guidelines that was designated as ‘Expert Opinion’ and also by various recommendations in the ACS/ASCO breast cancer survivorship care guideline (2016) related to the assessment and management of physical and psychosocial long‐term and late effects of breast cancer and its treatment.
Ongoing assessment for toxicities/late effects
In patients with breast cancer ensure that follow-up care includes ongoing assessment and supportive care for possible long-term toxicities and late effects of adjuvant treatments (including secondary cancers, cardiovascular toxicity, lymphoedema, mental health (including distress, depression, anxiety, body image), sexual health, premature menopause, infertility, fatigue, weight gain, impaired cognitive function, musculoskeletal health, pain and neuropathy, and bone health).
No evidence-based source recommendation was identified for this topic, which was considered an important aspect of care. This practice point was developed using an expert consensus process. The practice point was informed by a source recommendation in the ESO-ESMO 2017 consensus guidelines that was designated as ‘Expert Opinion’ and also by various recommendations in the ACS/ASCO breast cancer survivorship care guideline (2016) related to the assessment and management of physical and psychosocial long‐term and late effects of breast cancer and its treatment.